RU2653478C2 - Способ улучшения функции печени - Google Patents

Способ улучшения функции печени Download PDF

Info

Publication number
RU2653478C2
RU2653478C2 RU2014152196A RU2014152196A RU2653478C2 RU 2653478 C2 RU2653478 C2 RU 2653478C2 RU 2014152196 A RU2014152196 A RU 2014152196A RU 2014152196 A RU2014152196 A RU 2014152196A RU 2653478 C2 RU2653478 C2 RU 2653478C2
Authority
RU
Russia
Prior art keywords
metformin
patient
methazolamide
treatment
combination
Prior art date
Application number
RU2014152196A
Other languages
English (en)
Russian (ru)
Other versions
RU2014152196A (ru
Inventor
Кен УОЛДЕР
Гай КРИППНЕР
Джофф НИКОЛСОН
Original Assignee
Найя Матаболик Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Найя Матаболик Инк. filed Critical Найя Матаболик Инк.
Publication of RU2014152196A publication Critical patent/RU2014152196A/ru
Application granted granted Critical
Publication of RU2653478C2 publication Critical patent/RU2653478C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2014152196A 2012-05-24 2013-03-15 Способ улучшения функции печени RU2653478C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
US201261666574P 2012-06-29 2012-06-29
US61/666,574 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Publications (2)

Publication Number Publication Date
RU2014152196A RU2014152196A (ru) 2016-07-20
RU2653478C2 true RU2653478C2 (ru) 2018-05-08

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014152196A RU2653478C2 (ru) 2012-05-24 2013-03-15 Способ улучшения функции печени

Country Status (15)

Country Link
US (2) US20150150855A1 (enExample)
EP (1) EP2854807A4 (enExample)
JP (2) JP6360826B2 (enExample)
KR (1) KR20150023405A (enExample)
CN (2) CN104487073A (enExample)
BR (1) BR112014029308A2 (enExample)
CA (1) CA2874513A1 (enExample)
CO (1) CO7160082A2 (enExample)
HK (1) HK1209051A1 (enExample)
MX (1) MX362111B (enExample)
NZ (2) NZ702645A (enExample)
RU (1) RU2653478C2 (enExample)
SG (2) SG11201407787VA (enExample)
WO (1) WO2013173859A1 (enExample)
ZA (1) ZA201408704B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660170T3 (es) 2007-01-25 2018-03-21 NAIA Metabolic, Inc. Sensibilizadores a la insulina y métodos de tratamiento
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2268721C2 (ru) * 2000-07-20 2006-01-27 Зольвай Фармасьютиклз Гмбх Способ выявления соединений, пригодных для лечения и/или профилактики ожирения
WO2008089521A1 (en) * 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
NZ702666A (en) * 2012-05-24 2016-08-26 Verva Pharmaceuticals Ltd A method of weight reduction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2268721C2 (ru) * 2000-07-20 2006-01-27 Зольвай Фармасьютиклз Гмбх Способ выявления соединений, пригодных для лечения и/или профилактики ожирения
WO2008089521A1 (en) * 2007-01-25 2008-07-31 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YОО J и др. Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children//Diabetes Res Clin Pract. 2008 Sep; 81(3): 321-6. doi: 10.1016/j.diabres.2008.05.006. Epub 2008 Jun 20. HYO JEONG OH и др. Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease//Korean J Hepatol. 2011, Mar; 17(1): 27-36. Published online 2011, Mar 21. doi: 10.3350/kjhep.2011.17.1.27. *

Also Published As

Publication number Publication date
EP2854807A4 (en) 2016-03-16
MX362111B (es) 2019-01-07
CN109498623A (zh) 2019-03-22
SG11201407787VA (en) 2014-12-30
JP6412241B2 (ja) 2018-10-24
WO2013173859A1 (en) 2013-11-28
KR20150023405A (ko) 2015-03-05
ZA201408704B (en) 2018-07-25
HK1209051A1 (en) 2016-03-24
SG10201705388XA (en) 2017-07-28
CO7160082A2 (es) 2015-01-15
MX2014014317A (es) 2015-08-10
US20150150855A1 (en) 2015-06-04
CA2874513A1 (en) 2013-11-28
RU2014152196A (ru) 2016-07-20
EP2854807A1 (en) 2015-04-08
JP2015517534A (ja) 2015-06-22
US20180333399A1 (en) 2018-11-22
JP6360826B2 (ja) 2018-07-18
NZ723206A (en) 2018-02-23
CN104487073A (zh) 2015-04-01
BR112014029308A2 (pt) 2017-06-27
NZ702645A (en) 2016-08-26
JP2018090589A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
JP6066144B2 (ja) 併用医薬
JP6442284B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
KR101934328B1 (ko) 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
EA022349B1 (ru) Фармацевтическая композиция, включающая ингибитор sglt2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
JP6412241B2 (ja) 肝機能改善法
RU2664442C2 (ru) Способ снижения веса
EP1905450A1 (en) Pharmaceutical composition containing ppar gamma agonist
AU2016206292B2 (en) A method of improving liver function

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200316